CTMX drug candidates Varseta-M and CX-801 show clinical progress

CTMX says Varseta-M, an EpCAM-targeting ADC, is advancing in late-line colorectal cancer with FDA Fast Track status, alongside combination and expansion studies. CX-801 is also progressing in late-line settings, with data indicating efficacy and a favorable safety profile.